ArticleCureus2025
Polysomnographic Analysis of Sleep-Disordered Breathing In Children With Mucopolysaccharidoses in Qatar: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Therapeutic Options for Pulmonary and Sleep Disorders in Mucopolysaccharidosis (MPS) Patients: A Narrative Review.Advances in respiratory medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSleep-disordered breathing (SDB) represents a critical complication in mucopolysaccharidoses (MPSs), with a reported global prevalence rate of 80%-90%. The multifactorial pathophysiology involves glycosaminoglycan deposition in upper airway tissues and complex skeletal alterations. Although SDB is frequently encountered among MPS patients, details on its prevalence and characteristics remain unknown in Qatar. This study highlights different aspects of SDB in our population.
methodsA retrospective chart review study was conducted on patients with a confirmed diagnosis of MPS aged one to 18 between September 2019 and July 2023 who underwent polysomnography (PSG) study at Sidra Medicine (Doha, Qatar). Clinical and PSG data were collected and summarized.
resultsThe cohort comprised 14 patients (50% male; mean age 8.2 years (range: 1.42-18.8); mean BMI 21.63 kg/m
conclusionThis first comprehensive analysis of SDB in Qatar's pediatric MPS population reveals high prevalence and severity rates comparable to international cohorts. These results emphasize the crucial need for polysomnographic screening and early therapeutic intervention in this population. Future prospective studies should evaluate short and long-term treatment outcomes and explore potential genotype-phenotype correlations in this demographically distinct cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.